文献速递神经肌肉病

靶向二代测序Panel在腓骨肌萎缩症诊断中的应用

Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease.
PubMed 文献 · Neurology · 2019-12-11

该前瞻性研究纳入两家三级转诊中心的220例患者,评估靶向NGS panel在腓骨肌萎缩症(CMT)及相关疾病中的分子诊断效果。结果显示30%的病例获得明确分子诊断,伦敦与爱荷华诊断率相似;GJB1、MFN2和MPZ突变占遗传确诊的39%。NGS panel对PMP22重复/缺失阴性病例的诊断有效。

要点

  • 靶向NGS panel在CMT中诊断率为30%,PMP22重复/缺失阴性病例可获遗传确诊。
  • GJB1、MFN2和MPZ突变占遗传确诊的39%,其余为多样基因突变。
  • 早发病、家族史阳性或近亲结婚、脱髓鞘性神经病者更易获得明确遗传诊断。

核心结论

  • 靶向NGS panel是CMT诊断的有效工具,在PMP22重复/缺失阴性病例中约三分之一可获得遗传确诊。

研究设计与样本

  • 前瞻性纳入两家三级转诊中心(伦敦n=120,爱荷华n=100)共220例患者,均已申请靶向CMT NGS panel作为诊断检测。

主要发现

  • 30%的病例(n=67)获得明确分子诊断(致病或可能致病变异),伦敦诊断率32%,爱荷华29%。
  • 另有33%的病例发现意义未明变异。
  • GJB1、MFN2和MPZ突变占遗传确诊的39%,其余阳性病例涉及SH3TC2、GDAP1、IGHMBP2、LRSAM1、FDG4、GARS及其他12个较少见基因。
  • PMP22、MPZ、MFN2、SH3TC2和FDG4的拷贝数变化也可被准确检测。
  • 早发病、神经病家族史阳性或近亲结婚、脱髓鞘性神经病者更可能获得明确遗传诊断。

临床怎么用

  • 对临床疑似CMT且PMP22重复/缺失阴性的患者,可应用靶向NGS panel以提高分子诊断率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effectiveness of targeted next-generation sequencing (NGS) panels in achieving a molecular diagnosis in Charcot-Marie-Tooth disease (CMT) and related disorders in a clinical setting. METHODS: We prospectively enrolled 220 patients from 2 tertiary referral centers, one in London, United Kingdom (n = 120), and one in Iowa (n = 100), in whom a targeted CMT NGS panel had been requested as a diagnostic test. PMP22 duplication/deletion was previously excluded in demyelinating cases. We reviewed the genetic and clinical data upon completion of the diagnostic process. RESULTS: After targeted NGS sequencing, a definite molecular diagnosis, defined as a pathogenic or likely pathogenic variant, was reached in 30% of cases (n = 67). The diagnostic rate was similar in London (32%) and Iowa (29%). Variants of unknown significance were found in an additional 33% of cases. Mutations in GJB1, MFN2, and MPZ accounted for 39% of cases that received genetic confirmation, while the remainder of positive cases had mutations in diverse genes, including SH3TC2, GDAP1, IGHMBP2, LRSAM1, FDG4, and GARS, and another 12 less common genes. Copy number changes in PMP22, MPZ, MFN2, SH3TC2, and FDG4 were also accurately detected. A definite genetic diagnosis was more likely in cases with an early onset, a positive family history of neuropathy or consanguinity, and a demyelinating neuropathy. CONCLUSIONS: NGS panels are effective tools in the diagnosis of CMT, leading to genetic confirmation in one-third of cases negative for PMP22 duplication/deletion, thus highlighting how rarer and previously undiagnosed subtypes represent a relevant part of the genetic landscape of CMT.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cortese A, Wilcox JE, Polke JM, et al. Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease. Neurology. 2019. PMID: 31827005. doi:10.1212/WNL.0000000000008672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。